Literature DB >> 12486224

ARF mutation accelerates pituitary tumor development in Rb+/- mice.

Kenneth Y Tsai1, David MacPherson, Douglas A Rubinson, Alexander Yu Nikitin, Roderick Bronson, Kim L Mercer, Denise Crowley, Tyler Jacks.   

Abstract

Mice heterozygous for the retinoblastoma (Rb) tumor suppressor gene develop pituitary and thyroid tumors with high penetrance. We demonstrate here that loss of the ARF tumor suppressor strongly accelerates intermediate lobe pituitary tumorigenesis in Rb heterozygous mice. These effects in the pituitary are greater than those conferred by p53 loss in that Rb+-;ARF-- mice display significantly more early atypical lesions than Rb+-; p53-- mice. Also, Rb+-;ARF-- compound mutants do not develop many of the novel tumors or precancerous lesions seen in Rb+-;p53-- compound mutants. Although complete loss of ARF expression is not obligatory for pituitary tumorigenesis in Rb+- mice, alterations of the ARF locus are observed in tumors from Rb+-;ARF+- mice, consistent with a selective advantage of ARF inactivation in this context. We conclude that inactivation of ARF acts more broadly than that of p53 in connecting abrogation of the Rb pathway to tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486224      PMCID: PMC139235          DOI: 10.1073/pnas.262499599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  64 in total

Review 1.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

2.  Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/- mice.

Authors:  W H Lee
Journal:  Genes Dev       Date:  1996-08-01       Impact factor: 11.361

3.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

4.  A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice.

Authors:  M L Fero; M Rivkin; M Tasch; P Porter; C E Carow; E Firpo; K Polyak; L H Tsai; V Broudy; R M Perlmutter; K Kaushansky; J M Roberts
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

5.  Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).

Authors:  H Kiyokawa; R D Kineman; K O Manova-Todorova; V C Soares; E S Hoffman; M Ono; D Khanam; A C Hayday; L A Frohman; A Koff
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

6.  Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis.

Authors:  E Y Lee; C Y Chang; N Hu; Y C Wang; C C Lai; K Herrup; W H Lee; A Bradley
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

7.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.

Authors:  D E Quelle; F Zindy; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

8.  Effects of heterozygosity for the Rb-1t19neo allele in the mouse.

Authors:  D J Harrison; M L Hooper; J F Armstrong; A R Clarke
Journal:  Oncogene       Date:  1995-04-20       Impact factor: 9.867

9.  Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein.

Authors:  K Martin; D Trouche; C Hagemeier; T S Sørensen; N B La Thangue; T Kouzarides
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

10.  Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin.

Authors:  M Harvey; H Vogel; E Y Lee; A Bradley; L A Donehower
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

View more
  9 in total

1.  Distinct E2F-mediated transcriptional program regulates p14ARF gene expression.

Authors:  Hideyuki Komori; Mitsuru Enomoto; Masataka Nakamura; Ritsuko Iwanaga; Kiyoshi Ohtani
Journal:  EMBO J       Date:  2005-10-06       Impact factor: 11.598

2.  Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice.

Authors:  Anna Lasorella; Gerson Rothschild; Yoshifumi Yokota; Robert G Russell; Antonio Iavarone
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

Review 3.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

4.  Cooperation between Rb and Arf in suppressing mouse retinoblastoma.

Authors:  Karina Conkrite; Maggie Sundby; David Mu; Shizuo Mukai; David MacPherson
Journal:  J Clin Invest       Date:  2012-04-09       Impact factor: 14.808

Review 5.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

Review 6.  Genetically engineered mouse models of pituitary tumors.

Authors:  David A Cano; Alfonso Soto-Moreno; Alfonso Leal-Cerro
Journal:  Front Oncol       Date:  2014-08-01       Impact factor: 6.244

7.  Differential requirement for dimerization partner DP between E2F-dependent activation of tumor suppressor and growth-related genes.

Authors:  Hideyuki Komori; Yasuko Goto; Kenta Kurayoshi; Eiko Ozono; Ritsuko Iwanaga; Andrew P Bradford; Keigo Araki; Kiyoshi Ohtani
Journal:  Sci Rep       Date:  2018-05-31       Impact factor: 4.379

8.  Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition.

Authors:  Deshui Jia; Arnaud Augert; Dong-Wook Kim; Emily Eastwood; Nan Wu; Ali H Ibrahim; Kee-Beom Kim; Colin T Dunn; Smitha P S Pillai; Adi F Gazdar; Hamid Bolouri; Kwon-Sik Park; David MacPherson
Journal:  Cancer Discov       Date:  2018-09-04       Impact factor: 38.272

Review 9.  Animal models of pituitary neoplasia.

Authors:  K E Lines; M Stevenson; R V Thakker
Journal:  Mol Cell Endocrinol       Date:  2015-08-28       Impact factor: 4.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.